Fortrea Holdings Inc.
$10.44
▼
-0.63%
2026-04-21 06:58:00
www.fortrea.com
NMS: FTRE
Explore Fortrea Holdings Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$976.14 M
Current Price
$10.44
52W High / Low
$18.67 / $3.97
Stock P/E
—
Book Value
$6.05
Dividend Yield
—
ROCE
-1.7%
ROE
-1.02%
Face Value
—
EPS
$-10.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
13,871
Beta
1.77
Debt / Equity
198.26
Current Ratio
0.98
Quick Ratio
0.98
Forward P/E
9.69
Price / Sales
0.32
Enterprise Value
$1.8 B
EV / EBITDA
43.4
EV / Revenue
0.66
Rating
Buy
Target Price
$13.03
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 2. | Royalty Pharma plc | $49.52 | 27.78 | $28.52 B | 1.91% | 8.21% | 13.2% | $50.08 / $31.58 | $15.11 |
| 3. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 4. | Pliant Therapeutics, Inc. | $1.29 | — | $79.87 M | — | -74.87% | -61.55% | $1.95 / $1.09 | $2.95 |
| 5. | Stoke Therapeutics, Inc. | $36.46 | — | $2.16 B | — | -5.71% | -2.37% | $40.22 / $7.34 | $5.98 |
| 6. | Trevi Therapeutics, Inc. | $15.4 | — | $1.96 B | — | -26.85% | -30.23% | $15.76 / $5.38 | $1.43 |
| 7. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 660.5 M | 701.3 M | 710.3 M | 651.3 M | 697 M | — |
| Operating Profit | 8.8 M | -3.7 M | -10.9 M | -24.8 M | -28 M | — |
| Net Profit | -32.5 M | -15.9 M | -374.9 M | -562.9 M | -61.2 M | — |
| EPS in Rs | -0.35 | -0.17 | -4.01 | -6.02 | -0.65 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.72 B | 2.7 B | 2.84 B | 2.84 B |
| Operating Profit | -30.6 M | -111.8 M | 53.2 M | 222.8 M |
| Net Profit | -986.2 M | -328.5 M | -25.2 M | 186.2 M |
| EPS in Rs | -10.55 | -3.51 | -0.27 | 1.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.72 B | 3.58 B | 4.33 B | 4.29 B |
| Total Liabilities | 2.15 B | 2.22 B | 2.62 B | 945.3 M |
| Equity | 563.5 M | 1.36 B | 1.71 B | 3.34 B |
| Current Assets | 897.2 M | 948.2 M | 1.25 B | 1.25 B |
| Current Liabilities | 913.3 M | 949.5 M | 778.4 M | 699 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 113.5 M | 262.8 M | 168.4 M | 82.7 M |
| Investing CF | 14.4 M | 251.6 M | -31.8 M | -54 M |
| Financing CF | -76.3 M | -497.8 M | -140.8 M | -6.3 M |
| Free CF | 88.3 M | 237.3 M | 128.1 M | 28.3 M |
| Capex | -25.2 M | -25.5 M | -40.3 M | -54.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 1% | -5.14% | 0.19% | — |
| Earnings Growth % | -200.21% | -1203.57% | -113.53% | — |
| Profit Margin % | -36.21% | -12.18% | -0.89% | 6.56% |
| Operating Margin % | -1.12% | -4.15% | 1.87% | 7.85% |
| Gross Margin % | 18.5% | 19.81% | 20.78% | 25.53% |
| EBITDA Margin % | -29.87% | -2.38% | 4.83% | 9.9% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.